Gurnet Point Capital Limited is private equity and venture capital firm.
Business Model: B2B
Revenue: $30M
Employees: 11-50
Address: 55 Cambridge Pkwy Ste 401
City: Cambridge
State: MA
Zip: 02142
Country: US
They partner with life science leaders who have the vision and drive to transform their businesses. Those leaders are born risk-takers. Original thinkers with big ideas and bigger ambitions. Explorers who question the status quo. They are driven to succeed and are uncompromising in their quest to make things happen, even if the solutions aren’t easy or obvious. They are leaders who know when they need a catalyst to achieve transformational growth. They seek a partner who shares their long-term vision and strengthens it with financial resources and commercial expertise, standing shoulder-to-shoulder with them for as long as it takes. One who speaks their language and has a history of building successful life science businesses in their own right. A like-minded team committed to helping them realize their vision.
Contact Phone:
+16175884900
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2022 | Fairtility | Series A | 0 |
12/2016 | Crossover Health | Venture Round | 92M |
11/2018 | Axcella | Series E | 0 |
8/2021 | Mahana Therapeutics | Series B | 0 |
12/2016 | Auregen BioTherapeutics | Venture Round | - |
4/2020 | Zikani Therapeutics | Series A | 0 |
3/2017 | BEFORE Brands | Series B | 0 |
6/2022 | Alladapt Immunotherapeutics | Venture Round | 0 |
10/2016 | BEFORE Brands | Series A | 13.1M |
9/2022 | Naveris | Series A | 33.4M |
10/2022 | Corium | Private Equity Round | - |
12/2020 | Tremeau Pharmaceuticals | Private Equity Round | - |
5/2015 | Axcella | Series C | 39M |
4/2018 | Zikani Therapeutics | Venture Round | 0 |
2/2020 | Alladapt Immunotherapeutics | Series C | 0 |
12/2020 | Naveris | Series A | - |
6/2022 | Alladapt Immunotherapeutics | Venture Round | 0 |
5/2022 | Fairtility | Series A | 0 |
8/2021 | Mahana Therapeutics | Series B | 0 |
12/2020 | Naveris | Series A | - |
12/2020 | Tremeau Pharmaceuticals | Private Equity Round | - |
4/2020 | Zikani Therapeutics | Series A | 0 |
2/2020 | Alladapt Immunotherapeutics | Series C | 0 |
11/2018 | Axcella | Series E | 0 |
4/2018 | Zikani Therapeutics | Venture Round | 0 |
3/2017 | BEFORE Brands | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|